Disease-modifying drugs for knee osteoarthritis: can they be cost-effective? by Losina, Elena et al.
 1 
Disease-modifying drugs for knee osteoarthritis: can they be cost-effective? 1 
  2 
Elena Losina, PhD 3 
Meghan E. Daigle, BS 4 
William M. Reichmann, PhD 5 
Lisa G. Suter, MD 6 
David J. Hunter, MBBS, PhD 7 
Daniel H. Solomon, MD, MPH 8 
Rochelle P. Walensky, MD, MPH 9 
Joanne M. Jordan, MD, MPH 10 
Sara A. Burbine, BA 11 
A. David Paltiel, PhD 12 
Jeffrey N. Katz, MD, MSc 13 
 14 
Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopaedic Surgery (EL, 15 
MED, SAB, WMR, JNK), Division of Infectious Disease (RPW), Section of Clinical Sciences, Division of 16 
Rheumatology, Immunology and Allergy (EL, DHS, JNK), Brigham and Women’s Hospital, Boston, MA; 17 
Harvard Medical School, Boston, MA (EL, DHS, RPW, JNK); Boston University School of Public Health, 18 
Boston, MA (EL, WMR); Yale University, New Haven, CT (LGS, ADP); University of Sydney, Sydney 19 
Australia (DJH); Massachusetts General Hospital, Boston, MA (RPW); Thurston Arthritis Research 20 
Center, University of North Carolina, Chapel Hill, NC (JMJ)  21 
 22 
 23 
 2 
elosina@partners.org (EL), medaigle@partners.org (MED), breich315@gmail.com (WMR), 1 
lisa.suter@yale.edu (LGS), david.hunter@sydney.edu.au (DJH), dsolomon@partners.org (DHS), 2 
rwalensky@partners.org (RPW), joanne_jordan@med.unc.edu (JMJ), sara.burbine@gmail.com (SAB), 3 
david.paltiel@yale.edu (ADP), jnkatz@partners.org (JNK) 4 
 5 
Word Count: 4,153 6 
 7 
Correspondence:  8 
Elena Losina, PhD 9 
Orthopaedic and Arthritis Center for Outcomes Research 10 
Brigham and Women’s Hospital 11 
75 Francis St. BC-4 12 
Boston, MA 02115 13 
elosina@partners.org 14 
(617) 732 - 5338 15 
 16 
Running Title: Can DMOADs be cost-effective? 17 
18 
 3 
ABSTRACT  1 
 2 
Objective: Disease-modifying osteoarthritis drugs (DMOADs) are under development. Our goal was to 3 
determine efficacy, toxicity, and cost thresholds under which DMOADs would be a cost-effective knee 4 
OA treatment. 5 
  6 
Design: We used the Osteoarthritis Policy Model, a validated computer simulation of knee OA, to 7 
compare guideline-concordant care to strategies that insert DMOADs into the care sequence. The 8 
guideline-concordant care sequence included conservative pain management, corticosteroid injections, 9 
total knee replacement (TKR), and revision TKR. Base case DMOAD characteristics included: 50% 10 
chance of suspending progression in the first year with a resumption rate of 10% in every subsequent 11 
year with 30% pain relief among those whose progression was suspended; 0.5%/year risk of major 12 
toxicity; and costs of $1,000/year. In sensitivity analyses, we varied the suspension of OA progression 13 
(20-100%), pain relief (10-100%), major toxicity (0.1-2%), and cost ($1,000-$7,000). Outcomes 14 
included costs, quality-adjusted life expectancy, incremental cost-effectiveness ratios (ICERs), and 15 
TKR utilization.  16 
 17 
Results: Base case DMOADs added 4.00 quality-adjusted life years (QALYs) and $230,000 per 100 18 
persons, with an ICER of $57,500/QALY. DMOADs reduced need for TKR by 16%. DMOAD cost-19 
effectiveness was most sensitive to combinations of the likelihoods of suspended OA progression and 20 
pain relief. DMOADs costing $3,000/year could achieve ICERs below $100,000/QALY if the likelihood 21 
of suspended OA progression was 20% and the likelihood of pain relief was 70%. At an annual cost of 22 
$5,000, the same ICERs could be attained if the likelihood of suspended OA progression and the 23 
likelihood of pain relief were both 60%.  24 
 4 
Conclusions: We find that cost, suspended progression, and pain relief are the key drivers of value for 1 
DMOADs. Plausible combinations of these factors could reduce the need for TKR and satisfy 2 
commonly cited cost-effectiveness criteria.  3 
 4 
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 5 
INTRODUCTION 1 
 2 
Knee osteoarthritis (OA) is a prevalent and costly disease characterized by structural changes in 3 
cartilage, bone, synovium, and other joint structures1. Symptomatic knee OA is a leading cause of 4 
disability, afflicting more than 9.3 million US adults aged 26 years and older2. The population at risk for 5 
knee OA is growing substantially due to the aging population, obesity epidemic, and an increasing rate 6 
of knee injuries in young, active individuals1,3-7.    7 
 8 
Current guidelines for knee OA care focus on pain relief and functional improvement and include the 9 
use of non-pharmacologic and pharmacologic therapies early in the course of the disease8-10. 10 
Pharmacologic therapies are only modestly efficacious and have significant associated toxicities. For 11 
example, non-steroidal anti-inflammatory drugs (NSAIDs) pose gastrointestinal and cardiovascular 12 
risks11-13. There are no currently approved OA treatments capable of slowing OA-related structural 13 
progression or delaying the need for total knee replacement (TKR). Several large pharmaceutical 14 
companies are in the late stages of developing and testing such disease-modifying OA drugs 15 
(DMOADs), and promising agents that may both halt progression and provide symptom relief 16 
are currently being studied14-17. 17 
 18 
In light of ongoing efforts to develop DMOADs, we sought to address several key questions: Can 19 
DMOADs be cost-effective, and if so, at what levels of efficacy, toxicity, and cost? How early in the 20 
course of treatment should DMOADs be initiated? Do DMOADs have the potential to reduce TKR 21 
utilization? To address these key issues, we propose a novel framework in which model-based 22 
evaluations of cost-effectiveness can be used to pre-evaluate new treatment strategies before the 23 
 6 
treatments are actually in widespread use. Estimating the effects of particular features of a medication 1 
on that medication’s cost-effectiveness can inform the design of trials and provide performance targets.  2 
3 
 7 
METHODS 1 
 2 
Analytic Overview 3 
 4 
We used the Osteoarthritis Policy (OAPol) Model, a validated state-transition computer simulation 5 
model, to compare clinical outcomes and costs for subjects receiving guideline-concordant treatments 6 
(the standard of care), to subjects receiving standard of care and DMOADs18,19. Outcomes included 7 
costs, quality-adjusted life expectancy (QALE), incremental cost-effectiveness ratios (ICERs, the ratio 8 
of change in costs to change in QALE), and TKR utilization. In conformity with accepted practice, 9 
strategies that increased cost while decreasing QALE relative to an alternative treatment strategy were 10 
referred to as “Dominated.” We performed the analysis from the health systems perspective (indirect 11 
costs were not included in the main analysis), with costs and QALE discounted at a rate of 3%/year, 12 
as recommended by the Panel on Cost-Effectiveness in Medicine20.  13 
 14 
The OAPol Model 15 
 16 
The OAPol Model is a Monte Carlo simulation with a one-year cycle length. The health states in the 17 
model are defined by knee OA severity, presence of knee pain, comorbidities, and obesity. Obesity is 18 
determined by body mass index (BMI): underweight (BMI < 18.5 kg/m2), non-obese (18.5 kg/m2 ≤ BMI < 19 
30 kg/m2), obese (30 kg/m2 ≤ BMI < 35 kg/m2), and severely obese (BMI ≥ 35 kg/m2). Each year, 20 
subjects may develop a comorbid condition, increase in BMI, progress in OA severity, and/or die. 21 
Progression of OA is defined as an increase by one Kellgren-Lawrence (K-L) radiographic grade and is 22 
dependent on obesity status and sex21. The model considers five comorbid conditions: coronary heart 23 
disease, diabetes mellitus, chronic obstructive pulmonary disease, cancer, and musculoskeletal 24 
 8 
disorders other than OA. The prevalences of these comorbid conditions depend on age, sex, 1 
race/ethnicity, and obesity22-24. Each subject is followed until death, which may occur in any health 2 
state. The OAPol Model uses underlying mortality rates from US life tables with excess mortality due to 3 
specific comorbid conditions removed. The life tables are stratified by sex and race/ethnicity25. 4 
Individuals with comorbid conditions, or who are underweight, obese, or morbidly obese have greater 5 
risk of death26,27. Subjects with knee OA may receive OA treatments, which are characterized by the 6 
ability to relieve pain and suspend the progression of OA, toxicity, and cost. OA treatments may carry 7 
major (e.g. gastrointestinal bleeding) and minor (e.g. dyspepsia, rash) toxicities, both of which decrease 8 
quality of life and increase costs. Major toxicities lead to regimen discontinuation and may also cause 9 
death.  10 
 11 
Each year, subjects accrue costs and changes in quality of life due to OA or OA-related treatments, 12 
other underlying medical conditions, or toxicity from treatment. Quality of life weights are assigned to 13 
capture preferences for health states; a value of 1.0 denotes a state of perfect health while a value of 14 
zero denotes health states that are preferentially equivalent to death28. Annual medical costs not 15 
directly attributable to knee OA treatment are based on number of comorbidities, obesity, and 16 
age22,23,29,30. These data are presented in Table 1. Running tallies of survival, quality-adjusted survival, 17 
and costs are maintained for each individual and then aggregated to compute average values for the 18 
cohort31. The following paragraphs describe the means of modeling the standard of care and DMOAD 19 
regimens.  20 
 21 
Guideline-concordant OA care (standard of care): The standard of care consists of four, sequentially 22 
more invasive regimens: conservative pain management, including NSAIDs, acetaminophen, 23 
supportive devices, and physical therapy (Regimen 1); corticosteroid injections (Regimen 2); primary 24 
TKR (Regimen 3); and revision TKR (Regimen 4)8-10. Subjects progress to the next regimen in the 25 
 9 
sequence only when the current treatment fails or if a major toxicity occurs. Failure of each regimen is 1 
assumed to be detected in the year it occurs. Fundamental treatment characteristics for the standard of 2 
care are presented in Table 1.  3 
 4 
[Suggested Figure 1 position] 5 
 6 
DMOADs: We evaluated treatment strategies where DMOADs were used after the first standard of care 7 
regimen and before the second standard of care regimen.  Figure 1 illustrates the treatment 8 
sequence for individuals receiving DMOADs.  There are two measures of DMOAD treatment 9 
efficacy: structural efficacy and pain relief. Structural efficacy is defined by a relative reduction in the 10 
probability of progressing from one K-L grade to the next. Subjects for whom DMOADs suspend OA 11 
progression (i.e. DMOADs exhibit structural efficacy) remain at their current K-L grade. Subjects in 12 
whom structural progression is suspended may also experience pain relief and a consequent reduction 13 
in costs and improvement in quality of life. To ensure a conservative approach with respect to the 14 
clinical value of DMOADs, we assume that DMOAD-related pain relief is restricted to subjects in whom 15 
knee OA progression is suspended. Delaying progression at earlier stages of the disease prevents 16 
decrements in quality of life associated with advanced OA (K-L grade 3 or 4). While on DMOADs, 17 
individuals accumulate annual treatment costs. Subjects experiencing toxicity (major or minor) have a 18 
decrement in quality of life for that year and incur costs to treat the toxicity. Major toxicity carries a small 19 
risk of death. Subjects are removed from DMOADs and move on to the next treatment in the sequence 20 
if DMOADs fail to suspend progression and that failure is detected or if a major toxicity occurs. Figure 2 21 
shows the OAPol Model process for subjects receiving DMOADs. 22 
 23 
[Suggested Figure 2 position] 24 
 10 
 1 
Base Case DMOAD Characteristics and Assumptions 2 
 3 
As recommended by the Panel in Cost-effectiveness Analyses in Health and Medicine, we chose 4 
“base case” estimates of DMOAD efficacy, cost, and toxicity based on extensive discussions 5 
with clinicians and review of available literature.  In the base case, we assumed that DMOADs 6 
suspended OA progression in 50% of subjects. Among those in whom DMOADs succeeded in 7 
suspending progression in the first year, there was a 10% failure rate of maintaining the suspension of 8 
progression in every subsequent year. We further assumed that once disease progression resumed, it 9 
could no longer be suspended via DMOADs. For the base case analysis we chose to anchor pricing for 10 
DMOADs at $1,000/year, similar to the cost of prescription NSAIDs30. In addition to the baseline cost of 11 
DMOADs, we also considered the cost of one office visit per year: $132 in the first year and $93 in 12 
subsequent years (reflecting higher costs for new patient visits)32. 13 
 14 
In practice, monitoring for drug failure is typically triggered when patients report the persistence or 15 
recurrence of pain. Since drug failures to suspend disease progression would be accompanied by pain, 16 
we therefore assumed that all DMOAD failures would be detected in the year they occurred, resulting in 17 
discontinuation of DMOADs and allowing subjects to advance to the next treatment regimen in the 18 
following cycle. We assumed the base case likelihood of pain relief was 30% given that progression 19 
was suspended (that is, 15% overall likelihood of pain relief). Among patients whose structural 20 
progression had been suspended due to DMOADs and who experienced initial pain relief, there was a 21 
1%/year chance of losing pain relief. The failure to sustain pain relief reflects a multitude of factors 22 
including suboptimal adherence and accumulation of additional risk factors such as injury.  23 
 24 
 11 
We anchored values for both major and minor toxicities of DMOADs to NSAID toxicity characteristics. 1 
The cohort of individuals eligible to receive DMOADs will be similar to the population currently utilizing 2 
NSAIDs for OA pain; thus, acceptable DMOAD adverse event rates are likely to be comparable to 3 
those of NSAIDs. The likelihood of major toxicity was assumed to be 0.5% per year, based on the 4 
major toxicity risks of Cox-2 selective NSAIDs11,33. DMOAD minor toxicity was modeled after the toxicity 5 
of non-selective NSAIDs, with 9.50% risk in the first year, and 7.27% risk in all subsequent years34,35. In 6 
the base case analysis, we assumed that annual imaging studies to detect failure were included in the 7 
cost of the DMOAD regimen. We varied each of DMOAD parameters listed in Table 1 over the entire 8 
range reported in the table.  9 
 10 
[Suggested Table 1 Position] 11 
 12 
Cohort Characteristics 13 
 14 
We considered cohorts with a mean age of 53.4 years (standard deviation 14.4 years), based on 15 
estimates of the average age of OA diagnosis in the US36. Race/ethnicity, sex, and obesity distributions 16 
for persons with diagnosed knee OA were derived from the National Health Interview Survey 2007-17 
200824. In the absence of efficacious DMOADs, annual OA progression rates (percentage of subjects 18 
who worsened in K-L grade in a year) ranged from 1.29% for non-obese K-L grade 3 males to 12.26% 19 
for obese K-L grade 2 males19. Annual underlying (not related to OA management) medical costs (USD 20 
2010) ranged from $1,302 for young subjects with at most one comorbid condition and no OA pain to 21 
$18,877 for older subjects with symptomatic OA and greater than three comorbid conditions22,23,30,37-39. 22 
Quality of life weights were derived by converting responses to general health status questions in the 23 
National Health and Nutrition Examination Survey (NHANES) 2005-2008 to health status ratings on a 24 
 12 
scale of zero to 1.022,23,40,41. These ratings were then transformed to preference-based utilities42. The 1 
values ranged from 0.95 for young, healthy subjects with no OA pain to 0.66 for older subjects with 2 
several comorbidities and knee pain. Advanced knee OA (defined as symptomatic K-L grades 3 or 4) 3 
had a quality of life weight of 0.6943. Prevalence data for comorbid conditions were derived from 4 
NHANES 2005-200822,23. Table 1 summarizes select cohort input characteristics; additional details 5 
have been published elsewhere18,19. Please refer to the supplementary technical appendix for 6 
more information. 7 
 8 
Sensitivity Analyses 9 
 10 
Two-way Sensitivity Analyses of DMOAD Characteristics 11 
We conducted 21 sets of two-way sensitivity analyses, varying likelihood of suspending OA 12 
progression, pain relief, major toxicity, loss of pain relief and/or resumption of OA progression, and 13 
costs. We tested the sensitivity of DMOAD cost-effectiveness to variations in the initial likelihood of 14 
suspended progression (20% - 100%), failure to suspend progression in subsequent years (1% - 10%), 15 
initial pain relief (10% - 100%), failure to relieve pain in subsequent years (1% - 10%), cost ($1,000 - 16 
$7,000), and major toxicity (0.1% - 2%) in a series of two-way sensitivity analyses. By modeling 17 
DMOADs with low levels of pain relief (10%), we incorporated the possibility that DMOADs may 18 
not necessarily provide pain relief, even if they suspend progression. These ranges were 19 
chosen to cover the spectrum of possible DMOAD characteristics.  Costs and toxicity were 20 
specifically anchored to known values for NSAIDs. 21 
 22 
Additional Sensitivity Analyses 23 
 13 
In addition to varying levels of DMOAD efficacy, toxicity, and cost, we varied the timing of DMOAD 1 
administration, defined by where in the sequence of current standard of care DMOADs are inserted. 2 
We also varied the placement of the regimens by switching the order of Regimen 1 (NSAIDs, 3 
physical therapy, acetaminophen) and Regimen 2 (cortico-steroid injections).  We also tested 4 
the effect of removing Regimen 2 (cortico-steroid injections) from the treatment sequence. 5 
 6 
In a separate sensitivity analysis, we examined the value of DMOADs varying the baseline K-L 7 
grade distribution: (1) initialized with 100% K-L grade 1 OA, and (2) initialized with 50% K-L 8 
grade 1 and 50% K-L grade 2 OA.   9 
 10 
Finally, we conducted a sensitivity analysis using data for doxycycline, which has been 11 
suggested to have disease-modifying properties44. The published study showed that 12 
doxycycline could reduce progression by up to 40% while doxycycline has not been shown to 13 
have any effect on symptoms. We modeled minor gastrointestinal toxicities (the most 14 
significant toxicity reported in the study) occurring at a rate of 7% annually. Costs were 15 
estimated at $200 annually according to the Red Book30. 16 
17 
 14 
RESULTS 1 
 2 
Base Case Analysis (Table 2, top row) 3 
 4 
Clinical Benefits of DMOADs: The QALE among persons with knee OA who received the standard of 5 
care was estimated at 14.21 quality-adjusted life years (QALYs) discounted (22.22 QALYs 6 
undiscounted). Adding base case DMOADs as the second-line regimen in the treatment sequence 7 
(after NSAIDs and physical therapy but before corticosteroid injections) led to an estimated QALE 8 
of 14.25 QALYs. 9 
 10 
Among knee OA patients receiving the current standard of care, 11.00% underwent TKR within 10 11 
years of treatment initiation with a 52.37% lifetime risk of primary TKR. Adding base case DMOADs as 12 
the second-line regimen reduced the 10-year risk of TKR by 46%, with 5.99% of the DMOADs cohort 13 
receiving TKR within 10 years of treatment initiation. Moreover, DMOADs reduced lifetime risk of TKR 14 
by 15%, with 44.35% of the DMOADs cohort receiving primary TKR.  15 
 16 
Cost-effectiveness of DMOADs: Priced at $1,000 annually, the cost-effectiveness of DMOADs offered 17 
as the second-line regimen for those diagnosed with knee OA was estimated at $57,500/QALY gained.  18 
 19 
[Suggested Table 2 Position] 20 
 21 
Guidance for the Prospective Evaluation of DMOADs Regimens 22 
 23 
 15 
[Suggested Figure 3 Position] 1 
 2 
Figure 3 shows the minimal degree of structural OA progression suspension and pain relief at which 3 
DMOADs might be considered cost-effective using three different cost-effectiveness thresholds: 4 
$50,000/QALY, $100,000/QALY, and $150,000/QALY. Assuming DMOADs are associated with 0.5% 5 
risk of major toxicity and failure of DMOADS is diagnosed in the year it occurs, DMOADS costing 6 
$1,000/person/year would achieve ICERs below $50,000/QALY if they could suspend OA progression 7 
by at least 60% and provide concurrent pain relief in at least 30% of those with suspended OA 8 
progression. DMOADs that cost $3,000 or $5,000 would attain ICERs below $100,000/QALY if they 9 
could suspend OA progression/lead to pain relief by at least 20%/70% or 60%/60%. ICERs below 10 
$150,000/QALY could be achieved by DMOADs costing $7,000/person/year if they could suspend 11 
structural progression by at least 20% and lead to concomitant pain relief in at least 90% of those with 12 
suspended OA progression. Figure 3 shows that DMOADs costing $1,000, suspending progression in 13 
100% of cases, and leading to 20% pain relief would provide similar value as more expensive DMOADs 14 
($3,000/person/year) that suspend progression in 20% of cases, and relieve pain in 70% of cases. The 15 
same value would also be achieved by a more expensive DMOAD ($5,000) with pain relief and  16 
suspended progression at 60%. DMOADs costing $7,000 were unlikely to attain ICERs of 17 
$50,000/QALY, even if they were 100% effective in both suspending structural progression and 18 
relieving pain.  19 
 20 
Sensitivity Analyses 21 
 22 
Select, 2-way sensitivity analyses are presented in Figure 4 and Tables 2 and 3. Additional 2-way 23 
sensitivity analyses are presented in the Technical Appendix. The timing of DMOAD administration 24 
 16 
(anywhere in the sequence prior to TKR) did not have a meaningful impact on the cost-effectiveness of 1 
DMOAD therapy (results not shown).  2 
 3 
Table 2 presents results of two-way sensitivity analyses that varied the degree of suspended 4 
progression and pain relief within clinically plausible ranges (50-70% for suspended progression and 5 
30-50% for pain relief). When DMOADs were priced at $1,000/year with major toxicity risks at 6 
0.5%/year, DMOADs were likely to have cost-effectiveness ratios below $100,000 compared to the 7 
standard of care (no DMOADs). The proportion of the cohort receiving TKR depended on the likelihood 8 
that DMOADs suspended progression; base case DMOADs as the second-line regimen (50% 9 
suspended progression, 30% concomitant pain relief) resulted in 40.72% lifetime risk for TKR. 10 
Increasing suspended progression to 70% decreased lifetime risk of TKR to 37.82%. Figure 3 (upper 11 
left box) portrays cost-effectiveness ratios of DMOADs-based strategies for expanded ranges of 12 
suspended progression and pain relief. Results of these 2-way sensitivity analyses suggest that pain 13 
relief 10% or lower led to a lower QALE in patients receiving DMOADs compared to those who did not 14 
have DMOADs-based regimen as a part of their treatment strategy. Pain relief levels of 20% or lower 15 
resulted in either lower QALE (in scenarios where suspended OA progression was <50%) or ICERs 16 
greater than $150,000, if suspended progression rates ranged from 50-70%.  17 
 18 
[Suggested Figure 4 Position] 19 
 20 
Figure 4 also suggests that the cost-effectiveness of DMOADs was very sensitive to the degree of initial 21 
pain relief and loss of pain relief benefits in subsequent years, if initial pain relief was between 30-50%. 22 
Major toxicity rates played an important role, especially if levels of suspended progression were modest 23 
(20-50%).  24 
 17 
 1 
[Suggested Table 3 Position] 2 
 3 
Table 3 presents results of two-way sensitivity analyses examining the impact of DMOAD cost, efficacy, 4 
and toxicity. Improved pain relief (50%) achieved concurrently with suspended progression of 50% led 5 
to very favorable cost-effectiveness ratios (<$50,000/QALY); however, ICERs increased over 6 
$50,000/QALY when DMOADs were priced at $2,000 or $3,000 annually. Priced at $1,000/year, 7 
DMOADs had favorable ICERs across a wide range of plausible values for pain relief, toxicity, and 8 
likelihood of suspended progression.  9 
 10 
ICERs for DMOADs did not vary significantly when we varied the order of the regimens.  When 11 
cortico-steroid injections (Regimen 2) were received before NSAIDs, physical therapy, and 12 
acetaminphen (Regimen 1) in the treatment sequence, DMOADs still carried an ICER of 13 
$65,000/QALY.  If cortico-steroid injections were removed from the treatment sequence 14 
altogether, DMOADs carried an ICER of $31,000/QALY.   15 
 16 
Altering K-L grade distribution at the time of knee OA diagnosis did not lead to qualitative 17 
changes in ICERs. The DMOAD ICERs for cohorts who were 100% K-L grade 1 at the time of 18 
diagnosis were $38,000/QALY.  The ICER for the 50% K-L grade 1 and 50% K-L grade 2 cohort 19 
was $43,400/QALY.  20 
 21 
Results of the sensitivity analyses modeling Doxycycline as a potential DMOAD showed that 22 
doxycycline was a dominated strategy as it did not lead to meaningful improvements in quality 23 
of life. 24 
 18 
 1 
DISCUSSION  2 
 3 
Using the OAPol Model, a validated computer simulation of the epidemiology and management of knee 4 
OA, we have demonstrated that cost, efficacy, and pain relief are the key drivers of value in DMOADs. 5 
We also have shown how these drivers trade off with one another. In addition, we have described the 6 
many plausible combinations of these drivers which could reduce the need for TKR and satisfy 7 
commonly cited cost-effectiveness criteria. There is no general agreement about what defines “cost-8 
effective.” In the United States, maximum willingness-to-pay thresholds ranging from $50,000/QALY to 9 
$150,000/QALY and beyond are widely cited45-47. 10 
 11 
The cost-effectiveness of DMOADs was highly sensitive to variations in those parameters with direct 12 
effects on quality of life, particularly pain relief. Variations in the level of pain relief revealed a distinct 13 
threshold of 20%, below which DMOADs would not offer clinical benefits relative to standard care. 14 
DMOADs with no intrinsic pain-relieving capacity could only improve quality of life if slowing down 15 
progression ultimately reduced painful OA. Our results validate the importance of targeting pathways 16 
which will both reduce progression and offer pain relief.   17 
 18 
Since improvements in quality of life are anchored in pain relief, the cost-effectiveness of DMOADs 19 
ultimately depends on the level of overall symptom relief achieved by suspended structural progression. 20 
Greater rates of suspended OA progression were associated with a lower proportion of the cohort 21 
receiving TKR; however, the reduced TKR rates did not translate to greater cost-effectiveness unless 22 
DMOADs also offered pain relief because, while TKR is costly, it consistently provides pain relief. Thus, 23 
 19 
in order to justify prolonged DMOAD use before TKR, even in cases of suspended progression, 1 
DMOADs must offer pain relief. 2 
 3 
Several important limitations of our analyses should be considered when interpreting our results. Our 4 
measure for progression of OA was the K-L grade, which does not detect bone marrow lesions, 5 
significant contributors to OA pain48,49. While an MRI-based definition of OA and its progression is 6 
receiving growing attention, the validation of MRI-based markers is ongoing50. In order to address this 7 
limitation and maintain conservative estimates of pain relief, we did not model pain relief as 8 
automatically occurring in cases of suspended progression; rather, in the base case only 30% of 9 
subjects experiencing suspended progression also experienced pain relief. Moreover, in the model, the 10 
efficacy of DMOADs was expressed in terms of slowing or ‘suspending’ progression based on K-L 11 
grade. However, K-L grade is a relatively unresponsive marker of radiographic change and its use may 12 
lead to increased time until DMOAD failure detection51. Since conventional radiographs are a current 13 
standard of care, our analysis is consistent with clinical practice. Finally, we assumed that failure of 14 
DMOADs is detected in the year it occurs. While this assumption biases the results in favor of 15 
DMOADs, it seems reasonable since monitoring for failure is triggered by continuous or newly occurring 16 
pain.  17 
 18 
We were unable to incorporate the indirect costs of OA. We chose not to model indirect costs 19 
because, at present, there are no data available on the impact that DMOADs will have on 20 
disability or absenteeism.  As more data become available, this will be a rich area for future 21 
research.   22 
 23 
 20 
NHIS instruments did not allow for separation between knee OA and other sites and they did not 1 
distinguish OA from gout, RA and lupus and fibromyalgia which may distort somewhat sex, BMI 2 
and race distribution assigned to persons with knee OA. 3 
 4 
 5 
We did not consider high-tibial osteotomy (a treatment option for subjects with uni-6 
compartmental disease) as part of the standard treatment sequence.  In order to make results 7 
generalizable to the overall population with knee OA, we chose to simulate the most common 8 
OA treatments. 9 
 10 
The cost-effectiveness thresholds may vary from country to country. The results presented in 11 
this paper are based on cost and quality of life data measured in the US.  This paper offers a 12 
methodology that could be used to assess cost-effectiveness of DMOADs in other countries, 13 
using country specific data on OA natural history, progression and treatment costs.    14 
 15 
The results of our analyses showed that in the absence of DMOADs the lifetime risk of TKR among 16 
those with symptomatic knee OA approached 50%. These results suggest higher TKR rates than 17 
estimated in data derived from large cohort studies such as the Osteoarthritis Initiative (OAI)52. There 18 
are several reasons for the difference between our model-based estimates and OAI data: 1) persons 19 
intending to undergo TKR within 18 months were excluded from OAI, and 2) OAI-based estimates, 20 
which indicate a 1%/year conversion to TKR, include data from both incident and prevalent cohorts, 21 
with a substantial number of persons at K-L grade 1. In contrast, our model-based estimates used 22 
incidence of TKR data derived from the Multicenter Osteoarthritis Study (MOST) study, which assumes 23 
that only subjects with K-L grade 3 or greater were eligible for TKR. Among subjects in the OAI with K-L 24 
 21 
grade 3 or 4 OA, the conversion to TKR was estimated at about 10%/year52,53. Furthermore, this rate of 1 
conversion to TKR among those at K-L grade 3 or 4 was consistent with nationwide estimates of the 2 
number of TKRs performed in the US54. 3 
 4 
Although we only modeled the use of one DMOAD as part of the OA treatment sequence, it is likely that 5 
multiple DMOADs will ultimately become available to patients. It is also possible that DMOADs are 6 
more likely to offer pain relief for subjects who are K-L grade 2, before the degeneration of the knee 7 
joint reaches an advanced state, than for subjects who are K-L grade 3. However, we did not model 8 
varying levels of pain relief based on current K-L grade. In this case, it would be critical to offer 9 
DMOADs early in the treatment sequence, thus catching patients before they progress to more severe 10 
OA.  11 
 12 
To the best of our knowledge, the results of the analyses documented here comprise the first pre-13 
evaluation of the effectiveness, costs, and cost-effectiveness of DMOAD therapy for knee OA. We have 14 
examined the sensitivity of DMOAD value to variations in a wide spectrum of characteristics, most 15 
notably efficacy, toxicity, and costs. Our findings may provide critical insights for clinical trial planning 16 
and ensure that drug manufacturers focus the development of new regimens on parameters that will 17 
affect quality of life, in particular, pain relief. These analyses also offer a new approach in which 18 
simulation modeling can be efficiently used to evaluate new treatment strategies under development 19 
before the implementation of costly clinical trials.  20 
21 
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FIGURE LEGENDS 9 
 10 
Figure 1 11 
 12 
This figure shows the treatment sequence that each model subject will receive. Initially, 13 
subjects are on the first regimen, which consists of NSAIDs, acetaminophen, and physical 14 
therapy.  Each year on the regimen subjects are evaluated for regimen failure and for major 15 
toxicity.  If the regimen fails or a major toxicity occurs, the subject will be removed from the 16 
regimen and will move on either to the next regimen or to a post-treatment waiting period. 17 
Subjects will remain in the post-treatment waiting period until they are determined to be eligible 18 
for the next treatment.  Subjects in the DMOADs cohorts are eligible to receive DMOADs after 19 
the first regimen (subjects not in the DMOADs cohort move on to cortico-steroid injections).  20 
Once DMOADs fail to relieve pain or a major toxicity occurs, subjects move on to receive 21 
cortico-steroid injections, either immediately, or after a waiting period.  This process continues 22 
through to TKR.  Each year, subjects are evaluated for death; a subject may die at any point.  23 
 24 
Figure 2 25 
 26 
 29 
This figure depicts the pathway of a hypothetical subject in the OAPol Model receiving DMOADs. When 1 
DMOADs are discontinued, subjects will be evaluated for the treatment immediately following 2 
DMOADs.  3 
 4 
Figure 3 5 
 6 
Threshold efficacy, cost, and life expectancy associated with DMOADs treatment. This figure 7 
describes threshold efficacy for alternative willingness-to-pay thresholds, shown in blue 8 
($50,000/QALY), green ($100,000/QALY), and yellow ($150,000/QALY). Squares represent efficacy 9 
thresholds for DMOADs costing $1,000//person/year, triangles --$3,000/person/year, circles ---10 
$5,000/person/year, and diamonds -- $7,000/person/year. The vertical axis shows the per person 11 
discounted quality-adjusted life expectancy and the horizontal axis shows the per person discounted 12 
lifetime cost. The black square in the lower left corner represents the per person life expectancy and 13 
lifetime cost in a program with no DMOADs intervention. 14 
 15 
Figure 4 16 
 17 
Each box in Figure 3 represents a single two-way analysis – for instance varying cost ($1000 - $3000) 18 
and toxicity (0.1% - 2%) of DMOADs. The shade of each block in the quadrant represents the level of 19 
cost-effectiveness for that particular DMOAD in comparison to the standard of care. The darkest 20 
shades are the lowest levels of cost-effectiveness, and the lightest shades represent highest levels of 21 
cost-effectiveness. Blocks are shaded black if the particular DMOAD decreased QALE relative to the 22 
standard of care, and thus were dominated. The quadrants are organized such that the most beneficial 23 
 30 
combination of DMOAD parameters appears in the bottom right-hand corner of each square (for 1 
example, lowest cost, $1,000, and highest level of pain relief, 70%), and the least beneficial 2 
combination of DMOAD parameters appears in the top left-hand corner of each square (for example, 3 
highest cost - $3000, and lowest pain relief, 10%). 4 
 5 
6 
 31 
Table 1 Legend:  1 
†The lowest utility associated with the subject’s health state was used by the model; for example, a 45 year-old 2 
subject with severe OA and one comorbidity would have a utility of 0.690, whereas, the same subject with 3 3 
comorbidities would have a utility of 0.662. 4 
†† Efficacy for Regimens 1 and 2 applies only to individuals who are at K-L grade 2. 5 
†††Only pain relief efficacy associated with TKR is shown. TKR technical efficacy (e.g. stability of the implant) was 6 
greater than 98% for primary and revision TKR. 7 
‡Sensitivity analysis ranges for each parameter have been presented; base case values appear in bold within 8 
parentheses. 9 
‡‡Pain relief and suspended progression were 0% for subjects who have progressed to K-L grade 4. (K-L 4 10 
represents the most severe level of knee OA, thus patients cannot progress beyond it.) 11 
*Pain relief only occurred if there was also suspended progression. 12 
**Toxicity utilities and costs (2010 USD) were applied only in the year that the event occurred. 13 
 14 
 15 
 16 
Abbreviations: OA, osteoarthritis; K-L, Kellgren-Lawrence grade; NHANES, National Health and Nutrition 17 
Examination Survey; CPI, consumer price inflation calculator; MCBS, Medicare Current Beneficiary Survey; 18 
HCUP, Healthcare Cost and Utilization Project; DMOADs, disease-modifying osteoarthritis drugs 19 
Table 1. Select OAPol Model inputs  
Age at treatment initialization 
 (mean ± standard deviation) 53.54 ± 14.39   
Losina 201236 
OSTEOARTHRITIS PROGRESSION (annual likelihood, %) 
  
    K-L 2 to K-L 3 K-L 3 to K-L 4 
Holt 201119 Obesity Group Male Female Male Female 
Non-Obese 5.58 4.00 1.29 1.95 
Obese 12.26 8.95 2.94 4.27 
QUALITY OF LIFE UTILITIES 
  Utility for subjects with severe OA (K-L 3 or 4) 0.690 Losina 200943 
      
Non-Obese Obese 
  
  
Number of 
Comorbidities Age Group OA Pain 
No OA 
Pain OA Pain 
No OA 
Pain 
  
  
0 - 1  
25-44 0.814 0.955 0.781 0.921 
  
NHANES 2005-822,23  
  
  45-64 0.806 0.952 0.773 0.918 
  65+ 0.884 0.943 0.850 0.909 
  
2 -3 
25-44 0.721 0.903 0.688 0.870 
  45-64 0.713 0.901 0.679 0.867 
  65+ 0.791 0.891 0.757 0.858 
  > 3   0.662 0.662 0.662 0.662 
20 
 32 
 1 
ANNUAL DIRECT MEDICAL COSTS (USD 2010) 
  
Number of Comorbidities Age Group 
OA 
Pain 
No OA 
Pain   
Pope 200437 
NHANES 2005-822,23 
CPI 201038 
MCBS 200639 
Red Book 201030 
  
0-1 
25-34 $1,506 $1,302   
 
35-44 $2,018 $1,814 
   45-49 $2.635 $2,431   
 
50-54 $2,636 $2,432 
   55-59 $3,443 $3,239   
 
60-64 $4,144 $3,940 
 
 
65-69 $4,401 $4,198 
   70-74 $5,092 $4,888   
 
75-79 $5,916 $5,712 
 
 
80+ $7,709 $7,505 
   
2-3 
25-34 $6,856 $6,652   
 
35-44 $7,368 $7,165 
   45-49 $7,958 $7,755   
 
50-54 $7,959 $7,755 
   55-59 $8,436 $8,232   
 
60-64 $9,136 $8,933 
 
 
65-69 $9,060 $8,856 
 
 
70-74 $9,750 $9,547 
 
 
75-79 $10,575 $10,371 
   80+ $12,367 $12,163   
  
>3 
25-34 $12,710 $12,506   
 
35-44 $13,223 $13,019 
   45-49 $11,954 $11,751   
 
50-54 $11,955 $11,751 
   55-59 $13,105 $12,902   
 
60-64 $13,806 $13,602 
 
 
65-69 $15,570 $15,366 
 
 
70-74 $16,260 $16,056 
 
 
75-79 $17,084 $16,881 
   80+ $18,877 $18,673   
2 
 33 
 1 
STANDARD OF CARE TREATMENTS 
Regimen 1:   
NSAIDs, 
Acetaminophen, 
Physical 
Therapy, 
Assistive 
Devices 
  
First 
Year 
Subsequent 
Year Failure   
Pain Relief (annual, %)†† 64.00 24.00 Scott 200034 
  
First 
Year 
Subsequent 
Years   
Major Toxicity (annual, %) 0.38 0.38 Solomon 200511, Goldstein 199933 
Minor Toxicity (annual, %) 2.95 2.24 Bensen 1999
35, Scott 200034, 
Silverstein 199555 
Cost (USD 2010) $643  $483 
Medicare 201056-58, Redbook 
201030, MCBS 200639, Van Der 
Esch 200359, Grindrod 201060 
Regimen 2:   
Intra-articular 
Injections 
  
First 
Year 
Subsequent 
Year Failure 
 
  
Pain Relief (annual, %)†† 64.00 19.00 Raynauld, 200361 
  
First 
Year 
Subsequent 
Years   
Major Toxicity (annual, %) 0.00 0.00 Ayral, 200162 
Minor Toxicity (annual, %) 24.00 24.00 Ayral, 200162 
Cost†† (USD 2010) $437  $437 Medicare 201056-58, MCBS 200639 
Regimen 3:   
Primary TKR 
  
First 
Year 
Subsequent 
Year Failure   
Pain Relief (annual, %)††† 86.20 4.00 Katz 200763  
  
First 
Year 
Subsequent 
Years   
Major Toxicity (annual, %) 1.33 0.00 Paxton 201064, Katz 200465 
Minor Toxicity (annual, %) 2.94 0.00  Katz 200465 
Cost†† (USD 2010) $19,065 $90 
 Medicare 201056-58, HCUP 
200966, Buntin 200567, CPI 
201038, Teeny 200368 
Regimen 4:   
Revision TKR 
  
First 
Year 
Subsequent 
Year Failure   
Pain Relief (annual, %)††† 74.30 5.60  Katz 200763 
  
First 
Year 
Subsequent 
Years   
Major Toxicity (annual, %) 0.96 0.00 Paxton 201064, Katz 200465 
Minor Toxicity (%) 3.64 0.00  Katz 200465 
Cost†† (USD 2010) $24,631 $90 
 Medicare 201056-58, HCUP 
200966, Buntin 200567, CPI 
201038, Teeny 200368 
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 1 
DMOADS‡ 
      
1st Year Subsequent Years   
Annual Costs (Base Case) 
(USD 2010)           
  Overall $1,000 - $7,000 ($1,000)   
  Office Visits $132 $93 2010 Medicare Data
56-58 
Efficacy (Base Case) 
%, Annual 1st Year 
Subsequent 
Year Failure   
  
Halted Progression  
(K-L 2 – 3) ‡‡ 20 - 100 (50) 1 - 10 (10)   
  
Pain Relief* 
(K-L 2 – 3) ‡‡ 10 - 100 (30) 1 - 10 (1)   
Toxicity (Base Case) 
%, Annual 1st Year 
Subsequent 
Years   
  Major 0.5 - 2.0 (0.5)   
  Minor 9.50 7.27  Scott 200034, Bensen 199935 
Toxicity Outcomes           
  
Major 
Cardiovascular 
Likelihood 32.3     Solomon 200511 
  Mortality 6.02     HCUP 200869 
  Utility** 0.778     Sullivan 200670, NHANES 05-0822,23 
  Cost** $18,478      HCUP 200869, CPI 201038 
  
Gastrointestinal 
Likelihood 67.7     Goldstein 200033 
  Mortality 2.93     HCUP 200869 
  Utility 0.859     Jansen 200771, NHANES 05-0822,23 
  Cost $9,408      HCUP 200869, CPI 201038 
  
Minor General Minor Events 
Likelihood 100       
  Mortality 0       
  Utility 0.923     Jansen 200771, NHANES 05-0822,23 
  Cost $47      Kamath 200372, CPI 201038 
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 Table 2 Legend: 1 
*Standard of care sequence: conservative pain management (NSAIDs, acetaminophen, physical therapy), 2 
corticosteroid injections, primary TKR, revision TKR 3 
**Standard of care + DMOADs sequence: conservative pain management, DMOADs, corticosteroid injections, 4 
primary TKR, revision TKR 5 
‡Overall pain relief is calculated as (% pain relief given suspended progression) x (% suspended progression); the 6 
top row of this table corresponds with 30% pain relief given suspended progression, 50% suspended progression, 7 
and thus 15% overall pain relief. 8 
Abbreviations: ICER, incremental cost-effectiveness ratio; TKR, total knee replacement; SoC, standard of care 9 
 10 
11 Table 2. Two-way sensitivity analysis of DMOAD pain relief and suspended progression 
Suspended 
Progression Pain Relief Treatment Strategy 
Avg. 
QALE 
Avg. 
Cost ICER 
Proportion of 
Cohort Receiving 
Primary TKR 
50% 
Base Case 30% 
15% overall‡ 
Standard of Care* 14.21 $115,800  52.37% 
SoC + DMOADs** 14.25 $118,100 $57,500 44.35% 
       
40% 
20% overall 
Standard of Care 14.21 $115,800  52.37% 
SoC + DMOADs 14.28 $118,000 $31,400 44.34% 
       
50% 
25% overall 
Standard of Care 14.21 $115,800  52.37% 
SoC + DMOADs 14.32 $118,000 $20,000 44.33% 
        
60% 
30% 
18% overall 
Standard of Care 14.21 $115,800  52.37% 
SoC + DMOADs 14.26 $118,400 $52,000 42.82% 
       
40% 
24% overall 
Standard of Care 14.21 $115,800  52.37% 
SoC + DMOADs 14.31 $118,300 $25,000 42.82% 
       
50% 
30% overall 
Standard of Care 14.21 $115,800  52.37% 
SoC + DMOADs 14.35 $118,200 $17,100 42.83% 
         
70% 
30% 
21% overall 
Standard of Care 14.21 $115,800  52.37% 
SoC + DMOADs 14.28 $118,600 $40,000 41.31% 
       
40% 
28% overall 
Standard of Care 14.21 $115,800  52.37% 
SoC + DMOADs 14.33 $118,600 $23,300 41.31% 
       
50% 
35% overall 
Standard of Care 14.21 $115,800  52.37% 
SoC + DMOADs 14.38 $118,500 $15,900 41.31% 
 
 36 
Table 3 Legend: 1 
 2 
*Standard of care sequence includes: conservative pain management (NSAIDs, acetaminophen, physical 3 
therapy), corticosteroid injections, primary TKR, revision TKR 4 
**Standard of care + DMOADs sequence includes: conservative pain management, DMOADs, corticosteroid 5 
injections, primary TKR, revision TKR 6 
Abbreviations: DMOAD - disease modifying osteoarthritis drug; QALE - quality-adjusted life expectancy; ICER - 7 
incremental cost-effectiveness ratio; SoC – standard of care 8 
 9 
10 Table 3: Two-way sensitivity analysis of DMOAD cost and pain relief, suspended progression, or major toxicity 
        $1,000 $2,000 $3,000 
Treatment Strategy Avg. QALE 
Avg. 
Cost ICER 
Avg. 
Cost ICER 
Avg. 
Cost ICER 
Pa
in
 R
el
ie
f 
30% 
(base 
case) 
Standard of Care* 14.21 $115,800   $115,800   $115,800   
SoC + DMOADs** 14.25 $118,100 $57,500 $121,600 $145,000 $125,200 $235,000 
                  
40% 
Standard of Care 14.21 $115,800   $115,800   $115,800   
SoC + DMOADs 14.28 $118,000 $31,400 $121,600 $82,900 $125,100 $132,900 
                  
50% 
Standard of Care 14.21 $115,800   $115,800   $115,800   
SoC + DMOADs 14.32 $118,000 $20,000 $121,500 $51,800 $125,100 $84,500 
  
  
                
Su
sp
en
de
d 
Pr
og
re
ss
io
n 
50% 
(base 
case) 
Standard of Care 14.21 $115,800   $115,800   $115,800   
SoC + DMOADs 14.25 $118,100 $57,500 $121,600 $145,000 $125,200 $235,000 
                  
60% 
Standard of Care 14.21 $115,800   $115,800   $115,800   
SoC + DMOADs 14.26 $118,400 $52,000 $122,500 $134,000 $126,600 $216,000 
                  
70% 
Standard of Care 14.21 $115,800   $115,800   $115,800   
SoC + DMOADs 14.28 $118,600 $40,000 $123,300 $107,100 $128,000 $196,700 
  
  
                
M
aj
or
 T
ox
ic
ity
 
1% 
Standard of Care 14.21 $115,800   $115,800   $115,800   
SoC + DMOADs 14.24 $118,100 $76,700 $121,700 $196,700 $125,100 $310,000 
                  
0.5% 
(base 
case) 
Standard of Care 14.21 $115,800   $115,800   $115,800   
SoC + DMOADs 14.25 $118,100 $57,500 $121,600 $145,000 $125,200 $235,000 
                  
0.1% 
Standard of Care 14.21 $115,800   $115,800   $115,800   
SoC + DMOADs 14.26 $118,000 $44,000 $121,600 $116,000 $125,300 $190,000 
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Figure 1. The OAPol Model Treatment Sequence
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Post-
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* This regimen includes physical therapy, NSAIDs, and 
acetaminophen
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